These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 20926342)

  • 1. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.
    McDonnell DP; Wardell SE
    Curr Opin Pharmacol; 2010 Dec; 10(6):620-8. PubMed ID: 20926342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
    Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
    J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
    Patel HK; Bihani T
    Pharmacol Ther; 2018 Jun; 186():1-24. PubMed ID: 29289555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ; Johnston SR; Howell A
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.
    Park WC; Jordan VC
    Trends Mol Med; 2002 Feb; 8(2):82-8. PubMed ID: 11815274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).
    Wardell SE; Nelson ER; McDonnell DP
    Steroids; 2014 Nov; 90():30-8. PubMed ID: 25084324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
    Reiter R; Oh AS; Wellstein A; Riegel AT
    Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.
    Wang Y; Tang SC
    Cancer Metastasis Rev; 2022 Dec; 41(4):975-990. PubMed ID: 36229710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer.
    Katzenellenbogen BS; Katzenellenbogen JA
    Breast Cancer Res; 2000; 2(5):335-44. PubMed ID: 11250726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present).
    Scott JS; Barlaam B
    Expert Opin Ther Pat; 2022 Feb; 32(2):131-151. PubMed ID: 34763600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
    Lewis JS; Jordan VC
    Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer.
    Haines CN; Wardell SE; McDonnell DP
    Essays Biochem; 2021 Dec; 65(6):985-1001. PubMed ID: 34328178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
    McDaniel RE; Maximov PY; Jordan VC
    Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
    Lu Y; Liu W
    J Med Chem; 2020 Dec; 63(24):15094-15114. PubMed ID: 33138369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
    Jordan VC; O'Malley BW
    J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective estrogen receptor modulators: mechanism of action and clinical experience. Focus on raloxifene.
    Thiebaud D; Secrest RJ
    Reprod Fertil Dev; 2001; 13(4):331-6. PubMed ID: 11800172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Selective Estrogen Receptor Modulators in Breast Cancer Therapy: An Update.
    Das A; Lavanya KJ; Nandini ; Kaur K; Jaitak V
    Curr Med Chem; 2023; 30(29):3287-3314. PubMed ID: 36201273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs).
    Musa MA; Khan MO; Cooperwood JS
    Curr Med Chem; 2007; 14(11):1249-61. PubMed ID: 17504144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.
    Peng J; Sengupta S; Jordan VC
    Anticancer Agents Med Chem; 2009 Jun; 9(5):481-99. PubMed ID: 19519291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.